Search
pharmacologic agents for treatment of Parkinson's disease
Adverse effects:
- withholding Parkinson agents for surgery (Sinemet &/or dopaminergic receptor agonists) may result in parkinsonism-hyperpyrexia syndrome
- management includes restarting Parkinson agents [2,3]
Notes:
- simvastatin useless as disease-modifying Parkinsonian agent [4]
Specific
amantadine; adamantamine (Symmetrel, Gocovri)
benserazide (Serazide)
benztropine (Cogentin)
biperiden (Akineton)
bromocriptine (Parlodel, Cycloset)
carbidopa (Lodosyn)
combination therapy for Parkinson's disease
entacapone (Comtan)
L-deprenyl (Selegiline, Eldepryl, Emsam, Zelapar)
lazabemide (Tempium, Ro-19-6327)
levodopa; L-3-hydroxytyrosine; L-3,4-dihydroxyphenylalanine; L-dopa (Dopar, Larodopa, Inbrija)
opicapone (ONGENTYS)
pergolide (Permax, pergolidum)
piribedil (Trivastal)
pramipexole (Mirapex)
procyclidine (Kemadrin)
rasagiline (Azilect)
ropinirole (Requip, Requip-XL)
rotigotine (Neupro)
tolcapone (Tasmar)
trihexyphenidyl (Artane, Trihexy)
General
neurologic agent
References
- Prescriber's Letter 18(9): 2011
CHART: Comparison of Parkinson's Disease Drugs
CHART: Parkinson's Disease Therapy Algorithm
Detail-Document#: 270920
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
- Newman EJ, Grosset DG, Kennedy PG.
The parkinsonism-hyperpyrexia syndrome.
Neurocrit Care. 2009;10(1):136-40.
PMID: 18712508
- Stevens KN, Creanor S, Jeffery A et al
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With
Parkinson Disease. A Randomized Clinical Trial.
JAMA Neurol. Published online October 31, 2022
PMID: 36315128
https://jamanetwork.com/journals/jamaneurology/fullarticle/2797508